I n a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Silexion Therapeutics (SLXN) announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the ...

Short interest in Silexion Therapeutics Corp (NASDAQ:SLXN) decreased during the last reporting period, falling from 976.48K to 424.33K. This put 5.17% of the company's publicly available shares short.

Stay updated on market trends for SLXN. Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...